Skip to Content

HyQvia

Active Substance: human normal immunoglobulin
Common Name: human normal immunoglobulin
ATC Code: J06BA
Marketing Authorisation Holder: Baxalta Innovations GmbH
Active Substance: human normal immunoglobulin
Status: Authorised
Authorisation Date: 2013-05-16
Therapeutic Area: Immunologic Deficiency Syndromes
Pharmacotherapeutic Group: Immune sera and immunoglobulins

Therapeutic Indication

Replacement therapy in adults, children and adolescents (0-18 years) in:

  • Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).
  • Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.
  • Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.
  • Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT).

What is HyQvia and what is it used for?

HyQvia is used in patients with immunodeficiency syndromes. These are patients whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. HyQvia is used as ‘replacement therapy’ to treat:

  • primary immunodeficiency syndromes (PID, when patients are born with an inability to produce enough antibodies);
  • low levels of antibodies in the blood in patients who have chronic lymphocytic leukaemiaor myeloma (two cancers affecting different types of white blood cell) and who have frequent infections.

The product also contains recombinant human hyaluronidase, which is an enzyme used to help deliver the human normal immunoglobulin under the skin and improve its absorption into the body.

HyQvia contains the active substance human normal immunoglobulin.

How is HyQvia used?

HyQvia can only be obtained with a prescription and treatment should be started and monitored by a doctor or nurse experienced in treating immunodeficiency syndromes.

HyQvia is available as two solutions for infusion (drip) under the skin. A solution containing recombinant human hyaluronidase is given first and a solution containing human normal immunoglobulin (100 mg/ml) is then given by infusion in the same place. Detailed information about using HyQvia is provided in the package leaflet.

Patients or their carers may be able to give HyQvia themselves once they have been trained appropriately. The dose and frequency of infusions (how often it is given) depend on the individual patient and may need to be adjusted depending on their response.

How does HyQvia work?

The active substance in HyQvia, human normal immunoglobulin, is a highly purified protein extracted from the blood. It contains immunoglobulin G (IgG), which is a type of antibody. IgG has been used as a medicine since the 1950s and has a wide range of activity against organisms that can cause infection. HyQvia works by restoring abnormally low IgG levels to their normal range in the blood.

HyQvia also contains recombinant human hyaluronidase. This is a form of the natural human enzyme, hyaluronidase, which breaks down a substance called hyaluronic acid that is present in the tissues in the tiny spaces between cells and so makes the area between cells temporarily more liquid. When given under the skin before the normal human immunoglobulin, it helps to deliver the active substance under the skin, and assists its absorption into the body.

What benefits of HyQvia have been shown in studies?

Human normal immunoglobulin has been used to treat these diseases for many years. In accordance with current guidelines for these medicines, HyQvia was investigated in one main study lasting over a year and involving 89 patients with PID who had already had treatment with human normal immunoglobulin for at least three months. The main measure of effectiveness was the number of serious bacterial infections that developed over one year of treatment.

The study showed that HyQvia was able to reduce this number to 0.03 per year. This was below the predefined number needed to show effectiveness (which is one infection per year), and was similar to that seen with other licensed human normal immunoglobulin products.

This study was extended to almost 4 years and confirmed the long-term benefits and safety of HyQvia.

What are the risks associated with HyQvia?

The most common side effects with HyQvia (which may affect more than 1 in 10 people) are local reactions such as swelling and discomfort at the site of the infusion. For the full list of all side effects reported with HyQvia, see the package leaflet.

HyQvia must not be used in people who are hypersensitive (allergic) to normal human immunoglobulin or hyaluronidase or any of the other ingredients, or in patients who are allergic to other types of immunoglobulins, especially where they have deficiency (very low levels) of immunoglobulin A (IgA) and they have antibodies against IgA. HyQvia must not be given into a blood vessel or a muscle.

Why is HyQvia approved?

The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that HyQvia produces a similar reduction in the number of serious bacterial infections to that seen with other immunoglobulin products, and using recombinant hyaluronidase allows subcutaneous infusions to be given at much longer intervals, although local reactions are slightly more common. The possibility of patients or their carers giving the medicine themselves at home may also improve the convenience of the product. Although there had been concerns that antibodies that develop against recombinant hyaluronidase could cause side effects by affecting the natural version of the enzyme, the results of studies were reassuring. The Committee therefore decided that HyQvia’s benefits are greater than its risks and recommended that it be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of HyQvia?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of HyQvia have been included in the summary of product characteristics and the package leaflet.

Other information about HyQvia

The European Commission granted a marketing authorisation valid throughout the European Union for HyQvia on 16 May 2013.

For more information about treatment with HyQvia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide